Company intelligence / Profile preview

Tackle Bio

Ownership: Private
Development stage: Other

Overview

Tackle Bio is focused on rapidly developing treatments for COVID-19 and its long-term effects by repurposing existing approved drugs. The company leverages expertise in drug design and delivery to optimize these therapeutics for enhanced efficacy. No specific clinical results or trial data are publicly available as of now

Therapeutic areas: Infectious Diseases
Modalities: Small moleculeDrug repurposing (using already approved drugs)
Industry: Biotech

Beyond the preview

Go deeper on Tackle Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tackle Bio.

Explore the full profile